Compare Stocks
Ajanta Pharma announced Q3FY23 results
- Q3FY23:
- Revenue from operations at Rs 972 crore against Rs 838 crore; up 16%.
- EBITDA at Rs 170 crore against Rs 240 crore; EBITDA at 17% of revenue from operations.
- Adjusted EBITDA stands at Rs 207 crore against Rs 240 crore; Adjusted EBITDA at 21% of revenue from operations. This is after adjusting forex derivative loss of Rs 37 crore included in other expenses with forex gain in other income.
- Profit after tax at Rs 135 crore against Rs 192 crore; PAT at 14% of revenue from operations.
- 9MFY23:
- Revenue from operations at Rs 2,861 crore against Rs 2,471 crore, up 16%.
- EBITDA at Rs 588 crore against Rs 723 crore; EBITDA at 21% of revenue from operations.
- Adjusted EBITDA stands at Rs 631 crore against Rs 723 crore; Adjusted EBITDA at 22% of revenue from operations. This is after adjusting forex derivative loss of Rs 43 crore included in other expenses with forex gain in other income.
- Profit after tax at Rs 466 crore against Rs 561 crore, PAT at 16% of revenue from operations.
| Change YoY% | Dec 2022 | Sep 2022 | Dec 2021 | |
|---|---|---|---|---|
| Total Revenue Qtr cr | 16.8% | 1006.70 | 978.45 | 861.94 |
| Operating Profit Qtr Cr | -29.2% | 169.55 | 196.34 | 239.58 |
| Net Profit Qtr Cr | -29.9% | 134.51 | 156.60 | 191.78 |
| Basic EPS Qtr Rs | -52.6% | 10.50 | 12.22 | 22.16 |
